Impact of palbociclib plus letrozole on patient-reported health-related quality of life: results from the PALOMA-2 trial.

Document types check

Please use this identifier to cite or link to this item: https://hdl.handle.net/20.500.12530/38056

Title:	Impact of palbociclib plus letrozole on patient-reported health-related quality of life: results from the PALOMA-2 trial.
Authors:	Rugo, H S Diéras, V Gelmon, K A Finn, R S Slamon, D J Martin, M Neven, P Shparyk, Y Mori, A Lu, D R Bhattacharyya, H Bartlett, C Huang Iyer, S Johnston, S Ettl, J Harbeck, N View more
Issue Date:	1-Apr-2018
Citation:	Ann. Oncol..2018 Apr;(29)4:888-894
Abstract:	Patient-reported outcomes are integral in benefit-risk assessments of new treatment regimens. The PALOMA-2 study provides the largest body of evidence for patient-reported health-related quality of life (QOL) for patients with metastatic breast cancer (MBC) receiving first-line endocrine-based therapy (palbociclib plus letrozole and letrozole alone).
PMID:	29360932
URI:	https://hdl.handle.net/20.500.12530/38056
Rights:	openAccess
Appears in Collections:	Fundaciones e Institutos de Investigación > IIS H. General U. Gregorio Marañón > Artículos

Files in This Item:

File	Description	Size	Format
PMC5913649.pdf		299.27 kB	Adobe PDF	View/Open